Influence of high expression of Smac/DIABLO protein on the clinical outcome in acute myeloid leukemia patients

Leuk Res. 2010 Oct;34(10):1308-13. doi: 10.1016/j.leukres.2009.11.030. Epub 2010 Jan 12.

Abstract

The role of the Smac/DIABLO protein, a novel apoptosis agonist, in acute myeloid leukemia (AML) is not clearly determined. The expression of Smac/DIABLO protein in AML leukemic cells and its relationship with clinical outcome was evaluated in this study. The intracellular expression of Smac/DIABLO protein was assessed using multi-color flow cytometry in 71 newly diagnosed AML patients treated with conventional chemotherapy. It was found that the high expression of Smac/DIABLO protein was an independent prognostic factor in terms of higher complete remission rate (p<0.001) and longer overall survival (p=0.003). Moreover the low expression of Smac/DIABLO protein was associated with poor karyotype.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Apoptosis Regulatory Proteins
  • Female
  • Flow Cytometry
  • Humans
  • Intracellular Signaling Peptides and Proteins / analysis*
  • Intracellular Signaling Peptides and Proteins / genetics
  • Leukemia, Myeloid, Acute / drug therapy
  • Leukemia, Myeloid, Acute / metabolism
  • Leukemia, Myeloid, Acute / mortality*
  • Male
  • Middle Aged
  • Mitochondrial Proteins / analysis*
  • Mitochondrial Proteins / genetics
  • Risk Factors
  • Treatment Outcome

Substances

  • Apoptosis Regulatory Proteins
  • DIABLO protein, human
  • Intracellular Signaling Peptides and Proteins
  • Mitochondrial Proteins